Navigation Links
Live Recombinant Adenovirus Vaccine Technique Explored

Researchers at the Johns Hopkins Bloomberg School of Public Health are exploring ways to develop new vaccines for a variety of illnesses using genetically modified adenoviruses, a common cause of respiratory infections. Oral adenovirus vaccines have long been proven to be safe and effective. The researchers believe their process for constructing a replicating live recombinant adenovirus could lead to more economical vaccines that provide longer-lasting disease protection, which would be particularly beneficial for people living in the developing countries where resources are limited. Their research was made available online March 14, 2005, in advance of publication in the Proceedings of the National Academy of Sciences.

“Many vaccines are expensive to manufacture, require trained personnel to administer and multiple doses to provide immunity, which is not feasible for people living in many parts of the world,?explained Gary Ketner, PhD, senior author of the study and professor with the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. “The military developed oral vaccines for adenovirus years ago that safely provide immunity in one dose. We wanted to see if we could combine the safe and easy-to-use qualities of live adenovirus vaccine with the versatility of recombinant adenovirus virus vaccines that are being developed.?/p>

Specifically, Dr. Ketner and his colleagues hope to develop a vaccine for human papillomavirus (HPV) that could be used in the developing world. HPV causes 500,000 cases of cervical cancer each year worldwide. Recombinant HPV vaccines currently in clinical trials may not be ideal in poorer countries because they are expensive and require multiple immunizations.

The Hopkins researchers developed their vaccine prototype using canine oral papillomavirus (COPV), which behaves similarly to HPV. Research by other scientists showed that a vaccine consisting of recombinant
'"/>

Source:Johns Hopkins Bloomberg School Of Public Health


Page: 1 2

Related biology news :

1. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
2. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. New Vaccine To Be Used For First Time In Polio Outbreak Response
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Live Recombinant Adenovirus Vaccine Technique Explored

(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... York December 22, 2009): Interferon gamma is a protein ... in white blood cells that cause tuberculosis. In a ... NYU Langone Medical Center have discovered that in addition to ... cells, also respond to interferon gamma and also protect mice ...
... ground too fast and you will crash and burn; too slow ... monitoring the speed of images moving across their eyes. By slowing ... the retina remains constant, bees manage to control their approach. But ... how do bees adapt to landing on surfaces ranging from the ...
... Scott & White Healthcare in Temple, Texas, found that a new ... is unique in that it works both by stopping the cancer ... the immune system to destroy breast cancer cells and keeps them ... work in both ways, while all other treatments work in one ...
Cached Biology News:Final moments of bee landing tactics revealed 2Final moments of bee landing tactics revealed 3Scott & White Healthcare researcher finds success with new anti-cancer drug 2
(Date:4/21/2015)... April 21, 2015 Ampio Pharmaceuticals, Inc. (NYSE ... investor call on Thursday, April 23, 4:30 p.m. ET. ... as follows: Investor call information: ... 789-4877 International toll number: (925) 418-7845 Participant Passcode: 32888538 ... Tina Amirkiai , tina.amirkiai@fleishman.com . ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... that Dr. Mark W. Sawicki , ... 3rd Annual BioLogistics Summit in San ...
(Date:4/21/2015)... April 21, 2015  scPharmaceuticals, Inc., a ... products for subcutaneous delivery, announced today that ... its investigational proprietary drug product, Furosemide Injection ... with congestive heart failure. Concurrently ... a proprietary patch pump.  The patch pump ...
(Date:4/21/2015)... Bruno, CA (PRWEB) April 21, 2015 ... CRO, will sponsor and exhibit at the ACRP 2015 ... Salt Lake City, Utah. The Association of Clinical Research ... annual clinical research conference solely focused on the conduct ... membership, training and development, and widely recognized industry certifications. ...
Breaking Biology Technology:Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2
... Feb. 28 InterMune, Inc.,(Nasdaq: ITMN ) ... Officer of InterMune, will present at Susquehanna,s Second ... on March 5, 2008,at 2:30 p.m. EST., ... presentation, investors and other,interested parties may log on ...
... ... Feb. 28 Cepheid (Nasdaq:,CPHD) today announced financial results for the fourth quarter and full,year ... Total revenues of $129.5 million, a 48 percent increase from $87.4 ... - Total product sales of $116.5 million, a 41 percent increase from ...
... N.C., Feb. 28 PPD, Inc. (Nasdaq:,PPDI) today ... (NDA) for alogliptin, a highly selective DPP-4 inhibitor ... accepted for filing by the U.S.,Food and Drug ... Under PPD,s agreement with Takeda, the FDA,s ...
Cached Biology Technology:InterMune to Present at the SIGnificant Options in Healthcare Conference 2Cepheid Reports Fourth Quarter and Full Year 2007 Results 2Cepheid Reports Fourth Quarter and Full Year 2007 Results 3Cepheid Reports Fourth Quarter and Full Year 2007 Results 4Cepheid Reports Fourth Quarter and Full Year 2007 Results 5Cepheid Reports Fourth Quarter and Full Year 2007 Results 6Cepheid Reports Fourth Quarter and Full Year 2007 Results 7Cepheid Reports Fourth Quarter and Full Year 2007 Results 8Cepheid Reports Fourth Quarter and Full Year 2007 Results 9Cepheid Reports Fourth Quarter and Full Year 2007 Results 10Cepheid Reports Fourth Quarter and Full Year 2007 Results 11Cepheid Reports Fourth Quarter and Full Year 2007 Results 12Cepheid Reports Fourth Quarter and Full Year 2007 Results 13Cepheid Reports Fourth Quarter and Full Year 2007 Results 14PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Biology Products: